Summary
Transcription Factor 4 (TCF4) is a clinically pleiotropic gene associated with schizophrenia and Pitt-Hopkins syndrome (PTHS). To gain insight about the neurobiology of TCF4, we created an in vivo model of PTHS by suppressing Tcf4 expression in rat prefrontal neurons immediately prior to neurogenesis. This cell-autonomous genetic insult attenuated neuronal spiking by increasing the afterhyperpolarization. At the molecular level, using a novel technique called iTRAP that combined in utero electroporation and translating ribosome affinity purification, we identified increased translation of two ion channel genes, Kcnq1 and Scn10a. These ion channel candidates were validated by pharmacological rescue and molecular phenocopy. Remarkably, similar excitability deficits were observed in prefrontal neurons from a Tcf4+/tr mouse model of PTHS. Thus, we identify TCF4 as a regulator of neuronal intrinsic excitability in part by repression of Kcnq1 and Scn10a, and suggest this molecular function may underlie pathophysiology associated with neuropsychiatric disorders.
Disruption of the laminar and columnar organization of the brain is implicated in several psychiatric disorders. Here, we show in utero gain-of-function of the psychiatric risk gene transcription factor 4 (TCF4) severely disrupts the columnar organization of medial prefrontal cortex (mPFC) in a transcription- and activity-dependent manner. This morphological phenotype was rescued by co-expression of TCF4 plus calmodulin in a calcium-dependent manner and by dampening neuronal excitability through co-expression of the inwardly rectifying potassium channel (Kir2.1). For the first time, we show that NMDA receptor-dependent Ca2+ transients are instructive to minicolumn organization because Crispr/Cas9-mediated mutation of NMDA receptors rescued TCF4-dependent morphological phenotypes. Furthermore, we demonstrate that the transcriptional regulation by the psychiatric risk gene TCF4 enhances NMDA receptor-dependent early network oscillations. Our novel findings indicate that TCF4-dependent transcription directs the proper formation of prefrontal cortical minicolumns by regulating the expression of genes involved in early spontaneous neuronal activity, and thus our results provides insights into potential pathophysiological mechanisms of TCF4 associated psychiatric disorders.
The clinically pleiotropic gene, Transcription Factor 4 (TCF4), is a broadly expressed
basic helix-loop-helix (bHLH) transcription factor linked to multiple neurodevelopmental
disorders, including schizophrenia, 18q deletion syndrome, and Pitt Hopkins syndrome
(PTHS). In vivo suppression of Tcf4 by shRNA or mutation
by CRISPR/Cas9 in the developing rat prefrontal cortex resulted in attenuated action
potential output. To explain this intrinsic excitability deficit, we demonstrated that
haploinsufficiency of TCF4 lead to the ectopic expression of two ion channels,
Scn10a and Kcnq1. These targets of TCF4 regulation
were identified through molecular profiling experiments that used translating ribosome
affinity purification to enrich mRNA from genetically manipulated neurons.Using a mouse model of PTHS (Tcf4+/tr), we observed a
similar intrinsic excitability deficit, however the underlying mechanism appeared slightly
different than our rat model - as Scn10a expression was similarly
increased but Kcnq1 expression was decreased. Here, we show that the
truncated TCF4 protein expressed in our PTHS mouse model binds to wild-type TCF4 protein,
and we suggest the difference in Kcnq1 expression levels between these
two rodent models appears to be explained by a dominant-negative function of the truncated
TCF4 protein. Despite the differences in the underlying molecular mechanisms, we observed
common underlying intrinsic excitability deficits that are consistent with ectopic
expression of Scn10a. The converging molecular function of TCF4 across
two independent rodent models indicates SCN10a is a potential therapeutic target for
Pitt-Hopkins syndrome.
PurposeTo determine the effectiveness of etanercept, a tumor necrosis factor (TNF) inhibitor, in conferring neuroprotection to retinal ganglion cells (RGCs) and improving visual outcomes after optic nerve trauma with either optic nerve crush (ONC) or sonication-induced traumatic optic neuropathy (SI-TON) in mice.MethodsMouse optic nerves were unilaterally subjected to ONC (n = 20) or SI-TON (n = 20). TNF expression was evaluated by using immunohistochemistry and quantitative RT-PCR (qRT-PCR) in optic nerves harvested 6 and 24 hours post ONC (n = 10) and SI-TON (n = 10). Mice in each injury group received daily subcutaneous injections of either etanercept (10 mg/kg of body weight; five mice) or vehicle (five mice) for 7 days. Pattern electroretinograms were performed on all mice at 1 and 2 weeks after injury. ONC mice were killed at 2 weeks after injury, while SI-TON mice were euthanized at 4 weeks after injury. Whole retina flat-mounts were used for RGC quantification.ResultsImmunohistochemistry and qRT-PCR showed upregulation of TNF protein and gene expression within 24 hours after injury. In both models, etanercept use immediately following optic nerve injury led to higher RGC survival when compared to controls, which was comparable between the two models (24.23% in ONC versus 20.42% in SI-TON). In both models, 1 and 2 weeks post injury, mice treated with etanercept had significantly higher a-wave amplitudes than untreated injured controls.ConclusionsTreatment with etanercept significantly reduced retinal damage and improved visual function in both animal models of TON. These findings suggest that reducing TNF activity in injured optic nerves constitutes an effective therapeutic approach in an acute setting.
Traumatic optic neuropathy (TON) can occur following blunt trauma to the orbit and can lead to permanent vision loss. In this study, we investigated the effectiveness of elamipretide (MTP-131), a small mitochondrially-targeted tetrapeptide, in conjunction with etanercept, a tumor necrosis factor (TNF) inhibitor, as neuroprotective agents of retinal ganglion cells (RGCs) after optic nerve trauma with sonication-induced TON (SI-TON) in mice. Treatment with intravitreal MTP-131 and subcutaneous etanercept and MTP-131 showed a 21% increase (p<0.01) in RGC survival rate compared to PBS-treated control eyes. Subcutaneous etanercept and MTP-131 had an 11% increase (p<0.05) in RGC survival compared to controls. Subcutaneous etanercept only group showed 20% increase (p<0.01) in RGC survival compared to controls, while subcutaneous MTP-131 alone showed a 17% increase (p<0.01). Surprisingly, we did not observe a synergistic effect between the two drugs in the group receiving both etanercept and MTP-131. One possible explanation for the absence of a synergistic effect is that MTP-131 and etanercept may be acting on different portions of the same pathway.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.